Patent intelligence Β· HR
HR P20190642
ARIPIPRAZOLE PRODRUG COMPOSITIONS
ARIPIPRAZOLE PRODRUG COMPOSITIONS
Patent details β HR P20190642
- Jurisdiction
- HR
- Status
- granted
- Grant date
- May 31, 2019
- Expiration
- May 26, 2039
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100
Quick answer
HR P20190642 (ARIPIPRAZOLE PRODRUG COMPOSITIONS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 31, 2019. Expires May 26, 2039 (13 years remaining) β relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- β
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100, A61K/90019, A61K/9145
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
granted -
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
granted -
WO 2023154894
COMPOSITIONS ET PROCΓDΓS D'IMMUNOTHΓRAPIE ANTICANCΓREUSE
granted -
CY 2022006
Ξ Ξ‘ΞΞ¦ΞΞ‘ΞΞΞΞ Ξ¦ΞΞ₯ΞΞΞ‘ΞΞΩΠΞΞΞ΀ΩΠΞΞΞ Ξ Ξ§Ξ‘ΞΣΠ΀ΞΞ₯Ξ£ Σ΀ΞΞ ΞΞΞ©ΞΞ Ξ ΞΞΞΞΞΩΠΞΞΣΩΞ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent P20190642?
HR P20190642 (ARIPIPRAZOLE PRODRUG COMPOSITIONS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 31, 2019. Expires May 26, 2039 (13 years remaining) β relevant for patent-cliff and LOE planning.
Who owns HR P20190642?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does HR P20190642 expire?
Our index shows an expiration date of May 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.